Search results for "Thrombosis."

showing 10 items of 624 documents

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.

2021

Anti-A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS13) autoantibodies cause a severe ADAMTS13 deficiency in immune-mediated thrombotic thrombocytopenic purpura (iTTP). ADAMTS13 consists of a metalloprotease (M), a disintegrin-like (D) domain, 8 thrombospondin type 1 repeats (T1-T8), a cysteine-rich (C), a spacer (S), and 2 CUB domains (CUB1-2). We recently developed a high-throughput epitope mapping assay based on small, nonoverlapping ADAMTS13 fragments (M, DT, CS, T2-T5, T6-T8, CUB1-2). With this assay, we performed a comprehensive epitope mapping using 131 acute-phase samples and for the first time a large group of remission samples (n = 50). Ne…

MetalloproteinaseThrombospondinPurpura Thrombocytopenic IdiopathicbiologyPurpura Thrombotic Thrombocytopenicbusiness.industryThrombotic thrombocytopenic purpuraAutoantibodyHematologymedicine.diseaseADAMTS13Thrombosis and HemostasisCohort StudiesThrombospondin 1Epitope mappingImmune systemImmunologymedicineDisintegrinbiology.proteinHumansbusinessAgedAutoantibodiesBlood advances
researchProduct

More than Pneumonia: Distinctive Features of SARS-Cov-2 Infection. From Autopsy Findings to Clinical Implications: A Systematic Review

2020

Despite safety recommendations for the management of corpses with COVID-19 infection and the high number of deaths worldwide, the post-mortem investigation rate is extremely low as well as the scientific contributions describing the pathological features. The first results of post-mortem investigations provided interesting findings and contributed to promoting unexplored therapeutic approaches and new frontiers of research. A systematic review is provided with the aim of summarizing all autopsy studies up to February 2020 in which a complete post-mortem investigation in patients with COVID-19 disease was performed, focusing on histopathological features. We included case reports, case serie…

Microbiology (medical)medicine.medical_specialtyARDSAutopsyReviewDisease030204 cardiovascular system & hematologyCytokine stormMicrobiology03 medical and health sciences0302 clinical medicineautopsyVirologymedicineMedical historydiffuse alveolar damage (DAD)acute kidney injury (AKI)Intensive care medicineProspective cohort studyPathologicallcsh:QH301-705.5COVID-19; autopsy; diffuse alveolar damage (DAD); acute respiratory distress syndrome (ARDS); microthrombosis; acute kidney injury (AKI); cytokine stormmicrothrombosisbusiness.industryGold standardacute respiratory distress syndrome (ARDS)COVID-19medicine.diseasePneumonialcsh:Biology (General)030220 oncology & carcinogenesiscytokine stormmicrothrombosibusinessMicrothrombosis.Microorganisms
researchProduct

Vascular complications following bladder drained, simultaneous pancreas-kidney transplantation: the University of Miami experience

2000

Vascular complications remain a significant nonimmunologic source of pancreas allograft loss. From February 1993 through January 1998, we performed 98 simultaneous pancreas-kidney transplantations (SPK) using pancreatic exocrine bladder drainage in patients with type 1 insulin-dependent diabetes mellitus and end-stage renal disease. They originally received quadruple immunosuppression, and since May 1997 triple immunosuppression protocol (tacrolimus, mycophenolate mofetil, and steroids). The patients' mean age was 37 years (range 24-53 years), including 50 women and 48 men with a mean follow-up of 42 months. The overall rate of vascular complications was 6% (5 patients). The vascular compli…

NephrologyAdultMalemedicine.medical_specialtyTime FactorsUrinary BladderArteriovenous fistulaHospitals UniversityPseudoaneurysmMesenteric VeinsPostoperative ComplicationsMesenteric Artery Superiormedicine.arteryInternal medicinemedicineHumansDiabetic NephropathiesSuperior mesenteric arteryVascular DiseasesSuperior mesenteric veinRetrospective StudiesVenous ThrombosisTransplantationbusiness.industryAnticoagulantsMiddle Agedmedicine.diseaseThrombosisKidney TransplantationSurgerymedicine.anatomical_structureDiabetes Mellitus Type 1Splenic veinFloridaKidney Failure ChronicDrug Therapy CombinationFemalePancreas TransplantationPancreasbusinessAneurysm FalseImmunosuppressive AgentsSpleenTransplant International
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

2021

European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

ORAL ANTICOAGULANT-THERAPYmedicine.medical_specialtyELASTIC COMPRESSION STOCKINGSMEDLINEED AMERICAN-COLLEGEInferior vena cavaCATHETER-DIRECTED THROMBOLYSISBlood vessel prosthesisdeep-vein-thrombosisHeparin-induced thrombocytopeniamedicineYoung adultUPPER EXTREMITY DEEPbusiness.industryINFERIOR VENA-CAVAHEPARIN-INDUCED-THROMBOCYTOPENIAsilent pulmonary-embolismMOLECULAR-WEIGHT HEPARINVascular surgerymedicine.diseaseSurgeryClinical PracticeVenous thrombosismedicine.veinSurgeryCardiology and Cardiovascular MedicinebusinessEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.

2017

The diagnosis of essential thrombocythemia and polycythemia vera is often made during a thrombotic event which can be serious. Philadelphia-negative chronic myeloproliferative neoplasia patients have an increased thrombotic risk. This is assessed using various scoring systems but these are far from ideal and individual risk. The currend trend to personalised medicine requires finding the most useful thrombotic risk biomarker in these patients. Routine tests for coagulation do not take account of both pro- and anti-coagulant factors which is why these tests are not useful in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombin generation reflects more accurately the bal…

OncologyBlood PlateletsPathologymedicine.medical_specialtylcsh:Medicinemyeloproliferative neoplasmsGeneral Biochemistry Genetics and Molecular BiologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeDiagnosis Differential03 medical and health sciences0302 clinical medicinePolycythemia verapolycythemia veraCell-Derived MicroparticlesRisk Factorshemic and lymphatic diseasesInternal medicinemedicineBiomarkers TumorHumansThrombophiliaPlateletjak2 v617fMyeloproliferative neoplasmessential thrombocythemiaEssential thrombocythemiabusiness.industrylcsh:RThrombinThrombosispersonalized medicineJanus Kinase 2medicine.diseaseThrombosisCoagulationthrombin generation030220 oncology & carcinogenesisplateletsBiomarker (medicine)Personalized medicinebusinessthrombotic risk030215 immunologyBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

Metabolic disorders across hepatocellular carcinoma in Italy

2018

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, pati…

OncologyMaleobesityDatabases FactualHepatocellular carcinoma0302 clinical medicineRisk FactorsProspective cohort studydiabetesMetabolic disorderLiver NeoplasmsDiabeteshepatocellular carcinomaMiddle AgedMetabolic syndromePortal vein thrombosisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADiabetes; Hepatocellular carcinoma; Metabolic syndrome; Obesitymetabolic syndrome03 medical and health sciencesDatabasesMetabolic DiseasesInternal medicinemedicineDiabetes MellitusHumansObesityFactualAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseaseSurvival AnalysisBCLC Stagediabetes; hepatocellular carcinoma; metabolic syndrome; obesity; Aged; Carcinoma Hepatocellular; Databases Factual; Diabetes Mellitus; Female; Humans; Italy; Liver Neoplasms; Male; Metabolic Diseases; Middle Aged; Multivariate Analysis; Neoplasm Staging; Obesity; Retrospective Studies; Risk Factors; Survival AnalysisdiabeteMultivariate AnalysisLiver functionMetabolic syndromebusiness
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

1999

Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because < 55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelli…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)HematologyGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseThrombosis03 medical and health sciencesGynecologic malignancy0302 clinical medicinePort (medical)030220 oncology & carcinogenesisInternal medicinemedicineCoagulation testingcardiovascular diseasesbusinessCentral venous catheterThrombosis preventionClinical and Applied Thrombosis/Hemostasis
researchProduct